Möchten Sie immer auf dem neuesten Stand bleiben?

PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les...

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision...

Vergleichbare Langzeitwirksamkeit wie klassische Kortikosteroide, sowohl Prednison (p=0,8587) als auch Deflazacort (p=0,6544), basierend auf der Zeit bis zum Verlust der Gehfähigkeit80 % weniger...

Comparable long-term effectiveness to classic corticosteroids, both prednisone (p=0.8587) and deflazacort (p=0.6544), based on time to loss of ambulation80% fewer patients with vertebral fractures...

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus...

- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for...

- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that...

New York City, NY, March 08, 2026 (GLOBE NEWSWIRE) -- Memopezil is at the center of a rapidly growing conversation about cognitive health in 2026, as consumer interest in brain support has...

NEW YORK, March 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025...

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.

MagnesiumFreeze sciatic nerve claims examined: 2026 consumer research report on Magnesium Niacinamide Relief ingredients, NAD+ science, pricing.

Aqua Vital Filter and Aqua Vital Bottle claims evaluated with published research context, pricing disclosures, and consumer verification guide.

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously...

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October...

uniQure Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights If you purchased or...

2026 consumer report examines Karylief tinnitus supplement ingredients, proprietary blend transparency, pricing, refund terms, and research context.

Nooro NMES Foot Massager claims examined: FDA clearance context, NMES technology research, pricing, refund terms, and consumer verification steps.

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater...

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE). Shareholders who purchased shares of QURE during the...

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the...

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares of...

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Shareholders who purchased shares of INO...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aquestive (AQST) To Contact Him Directly To Discuss Their Options If you purchased or...

2026 consumer report evaluates Mind Vault brain formula ingredient research, senior cognitive support claims, and key verification considerations

Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate painIn both...

Investors who lost money in CORT after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

2026 consumer report examines CardioGLYX Blood Support ingredient research, blood sugar and cholesterol claims, pricing, and key considerations

LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...

New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.

BENSALEM, Pa., March 06, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...

2026 consumer report examines SleepZee anti-snoring mouthpiece mandibular advancement research, snoring reduction claims, and buyer checklist.

2026 consumer report evaluates EMF Shield Defense Pendant claims, 36-mineral negative ion technology, pricing, and key verification steps for buyers.

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE)What: Securities fraud class action lawsuit filedClass Period: September 24, 2025, and October 31, 2025Deadline to Seek Lead...

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Exton, PA, March 06, 2026 (GLOBE NEWSWIRE) -- New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as...

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...

FORT LAUDERDALE, FL, March 06, 2026 (GLOBE NEWSWIRE) -- February 28th is Rare Diseases Day. The observance helps shed light on thousands of underaddressed conditions across the United States and...

GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C...

         Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and...

FORT MILL, S.C., March 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that...

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients...

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the...

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug...